Article Sidebar
Date Published:
27/04/2023
Abstract Views: 469
Views PDF: 110
Views PDF: 110
Issue
Section
Các bài báo
How to Cite
Trần, T. ., & Nguyễn, T. H. . (2023). EVALUATE THE RESULTS OF XELIRI REGIMEN AFTER FAILURE WITH FIRST-LINE CHEMOTHERAPY FOR METASTATIC COLORECTAL CANCER. Vietnam Medical Journal, 525(2). https://doi.org/10.51298/vmj.v525i2.5161
EVALUATE THE RESULTS OF XELIRI REGIMEN AFTER FAILURE WITH FIRST-LINE CHEMOTHERAPY FOR METASTATIC COLORECTAL CANCER
Main Article Content
Abstract
Aims: Asscess treatment outcome and some side effects of XELIRI regimen in patients with metastatic colorectal cancer after failure to the first line chemotherapy. Patients and methods: 40 patients with metastatic colorectal cancer, after failure to the fist line chemotherapy, who was treated with XELIRI regimen, at National Cancer Hopstial, from 2018 to 2021. Results: The respond rate was 35%, the disease control rate was 85%, time to progression - free survival was 10 months, grade 3,4 toxicities such as diarrhea (10%), hand – foot syndrome (5), high live emzyms (2.5%).
Article Details
Keywords
metastatic colorectal cancer, XELIRI, second line.
References
1. Sung H FJ, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021 May (3): 209-249.
2. Trần Nguyên Bảo: Đánh giá đáp ứng điều trị hóa chất phác đồ FOLFOX 4 trên bệnh nhân ung thư đại trực tràng giai đoạn muộn. Tạp chí ung thư học Việt Nam 2013, số 2 - 2013:97 - 100.
3. Nguyễn Thị Kim Anh: Đánh giá kết quả điều trị ung thư đại trực tràng tiến triển bằng phác đồ FOLFOX tại Bệnh viện E. Đại học Y Hà Nội.; 2013.
4. Haller DG CJ, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM,, al e: Potential regional differences for the tolerability profiles of fluoropy‑rimidines. J Clin Oncol 2008, 26(13):2118–23.
5. Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geißler M, Hegewisch-Becker S, Tannapfel A, Pohl M: Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Annals of oncology 2013, 24(6):1580-1587.
6. Papagiorgis P, Oikonomakis I, Karapanagiotou I, Wexner S, Nikiteas N: The impact of tumor location on the histopathologic expression of colorectal cancer. Journal of BU ON: official journal of the Balkan Union of Oncology 2006, 11(3):317-321.
7. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. Journal of Clinical Oncology 2007, 25(30):4779-4786.
8. Kotaka M, Xu R, Muro K, Park YS, Morita S, Iwasa S, Uetake H, Nishina T, Nozawa H, Matsumoto H: Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. Chinese journal of cancer 2016, 35(1):1-8.
2. Trần Nguyên Bảo: Đánh giá đáp ứng điều trị hóa chất phác đồ FOLFOX 4 trên bệnh nhân ung thư đại trực tràng giai đoạn muộn. Tạp chí ung thư học Việt Nam 2013, số 2 - 2013:97 - 100.
3. Nguyễn Thị Kim Anh: Đánh giá kết quả điều trị ung thư đại trực tràng tiến triển bằng phác đồ FOLFOX tại Bệnh viện E. Đại học Y Hà Nội.; 2013.
4. Haller DG CJ, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM,, al e: Potential regional differences for the tolerability profiles of fluoropy‑rimidines. J Clin Oncol 2008, 26(13):2118–23.
5. Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geißler M, Hegewisch-Becker S, Tannapfel A, Pohl M: Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Annals of oncology 2013, 24(6):1580-1587.
6. Papagiorgis P, Oikonomakis I, Karapanagiotou I, Wexner S, Nikiteas N: The impact of tumor location on the histopathologic expression of colorectal cancer. Journal of BU ON: official journal of the Balkan Union of Oncology 2006, 11(3):317-321.
7. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. Journal of Clinical Oncology 2007, 25(30):4779-4786.
8. Kotaka M, Xu R, Muro K, Park YS, Morita S, Iwasa S, Uetake H, Nishina T, Nozawa H, Matsumoto H: Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. Chinese journal of cancer 2016, 35(1):1-8.